Clinical Trials Browser

Phase 1/2 × CX 5461 × Lymphoid × Clear all

NCT07069699 2026-03-18

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Phase 1/2 Recruiting

Burkitt Lymphoma